CYPH stock forecast, quote, news & analysis
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network... Show more
Cypherpunk Technologies (CYPH) Stock Analysis: Zcash Exposure Defines the Risk-Reward Equation
Key Takeaways
- Cypherpunk Technologies (CYPH) trades around $3.14, down roughly 5% over the trailing 30 days, a modest pullback after a much larger multi-month advance.
- Over the past quarter, the stock surged from about $0.69 in early August to current levels, a gain of roughly 350%, reflecting a sharp repricing of the company's Zcash strategy.
- The company is a privacy-technology vehicle whose valuation is tightly linked to the price of Zcash (ZEC), a relationship that cuts both ways.
- A second-quarter profit, driven by an unrealized gain on ZEC treasury holdings, and the August launch of the world's largest Zcash mining fleet were key catalysts.
- Concentration risk remains the central consideration: the company's fortunes are anchored to a single, thinly traded digital asset and its network economics.
- You can explore additional detail on Price Targets, Earnings, and Forecast pages for deeper context on CYPH.
- For AI-driven trading insights, explore Trending AI Robots.
Current Market Snapshot
Cypherpunk Technologies shares have settled near $3.14, easing about 5.3% from the $3.31 close recorded roughly 30 days earlier. The decline marks a period of consolidation after an extraordinary rally: in early August the stock traded near $0.69 before climbing more than threefold through September, reaching a peak above $4.00 before pulling back.
The stock's high-beta profile is a direct reflection of its business model. As a Nasdaq-listed company whose balance sheet and operating strategy are anchored to Zcash, CYPH behaves less like a conventional technology equity and more like a leveraged expression of sentiment toward privacy-focused digital assets. Broader cryptocurrency market conditions, Zcash network developments, and the company's own treasury and mining operations all feed into day-to-day price action.
Cypherpunk Technologies (CYPH) Business Overview and Competitive Position
Cypherpunk Technologies is a privacy-technology company whose stated mission is to advance technologies that guarantee privacy on the internet. The company pursues this through two primary strategies: accumulating Zcash (ZEC), a privacy-focused cryptocurrency, and investing in, acquiring, and building privacy-preserving technologies, including its ZODL Zcash wallet. The company was formerly known as Leap Therapeutics and adopted its current name and Nasdaq symbol in November 2025.
Cypherpunk has also retained a biotech arm through its Leap Therapeutics subsidiary, which is developing investigational cancer therapies. This dual exposure to digital assets and life sciences makes Cypherpunk an unusual, diversified holding.
Within the Zcash ecosystem, Cypherpunk holds a leading corporate position. As of August 2026, the company reported a treasury of 323,394 ZEC, representing approximately 1.92% of the circulating supply, with a stated goal of reaching 5% of total supply. Its launch of Cypherpunk Mining made it the largest corporate Zcash miner, operating roughly 18% of the network's hashrate.
Recent Developments Driving CYPH
The most significant recent development was the August 2026 launch of Cypherpunk Mining. Through a $33.33 million equity-based transaction with Winklevoss Capital, the company activated approximately 4.2 GSol/s of Equihash hashrate across U.S. facilities, positioning itself as the world's largest Zcash mining fleet and adding direct ZEC production to its existing treasury strategy. Industry veteran Kevin Zhang was appointed Head of Mining.
Financial results have also shaped sentiment. The company reported second-quarter net income of $39.4 million, or $0.18 per share, compared with a prior-year net loss, driven by a $46.0 million unrealized gain on the fair value of its ZEC holdings. This followed a difficult first quarter in which a decline in the ZEC price produced a substantial unrealized loss, underscoring how mark-to-market accounting of the treasury can swing results sharply from period to period.
Zcash network security has been another recurring factor. An earlier vulnerability identified in the Orchard shielded pool prompted a sharp sell-off in ZEC and Cypherpunk shares before developers issued an emergency patch and deployed the Ironwood upgrade in July to reinforce the network.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. While Tickeron offers hundreds of AI robots trading across thousands of tickers, only the top-performing and most relevant bots appear in this section, helping traders filter for strategies that are currently standing out. The bots vary in their approach, timeframe, and performance metrics, ranging from short-term pattern recognition to longer-horizon trend strategies. For investors tracking fast-moving and high-volatility names, reviewing these automated tools can offer an additional, data-driven perspective alongside fundamental research.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary driver of CYPH's valuation is likely to remain the price of ZEC and the health of the Zcash network. Because the treasury is marked to market each period, swings in ZEC directly affect reported earnings, making quarterly results inherently volatile.
Investors should also monitor mining economics, including hashrate, network difficulty, and energy costs, as well as the pace of the company's progress toward its 5% supply target. Regulatory developments affecting privacy-focused digital assets, exchange delistings, or compliance requirements could materially influence sentiment. On the biotech side, clinical progress from the Leap Therapeutics pipeline represents a secondary but potentially meaningful catalyst. Nasdaq listing and bid-price compliance considerations, together with the company's cash position relative to ongoing operating expenses, round out the key watch items for the year.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CYPH sees MACD Histogram just turned negative
CYPH saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 36 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYPH as a result. In 66 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
CYPH moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CYPH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CYPH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +21.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYPH advanced for three days, in 216 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. CYPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.228) is normal, around the industry mean (2.412). P/E Ratio (4.500) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.319). Dividend Yield (0.000) settles around the average of (0.270) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (15.694).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in clinical stage immuno-oncology
Industry InvestmentManagers